Salud financiera de hoja de balance de iBio

Salud financiera controles de criterios 5/6

iBio tiene un patrimonio de los accionistas total de $21.3M y una deuda total de $1.1M, lo que sitúa su ratio deuda-patrimonio en 5.2%. Sus activos y pasivos totales son $28.7M y $7.4M respectivamente.

Información clave

5.2%

Ratio deuda-patrimonio

US$1.11m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$14.21m
Patrimonio	US$21.32m
Total pasivo	US$7.41m
Activos totales	US$28.73m

Actualizaciones recientes sobre salud financiera

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($15.7M) de IBIO superan a sus pasivos a corto plazo ($3.8M).

Pasivo a largo plazo: Los activos a corto plazo de IBIO ($15.7M) superan a sus pasivos a largo plazo ($3.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IBIO tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de IBIO ha crecido de 0% a 5.2% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IBIO tiene suficiente cash runway para 10 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que IBIO disponga de suficiente cash runway para 6 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de iBio

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

iBio, Inc. announced delayed annual 10-K filing

iBio Regains Compliance with NYSE American Continued Listing Standards

Recent updates

iBio, Inc., Annual General Meeting, Nov 21, 2024

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

New major risk - Financial position

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

New major risk - Financial position

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New minor risk - Insider selling

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Consensus forecasts updated

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Price target decreased to US$1.75

Consensus revenue estimates fall by 52%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

Price target decreased to US$2.25

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020)

Independent Director Seymour Flug has left the company

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Revenue beats expectations

Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020)

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: US$2.17

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: US$1.08

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Price target lowered to US$2.00

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance